MORLENCIR ARCHIVE
Back to Morlencir Empire Reference Manual
Morlencir Empire Reference Manual

Medical Compatibility

Medical Compatibility and Cross-Species Clinical Reference

Internal Archive: Diegetic Lore

Purpose

This table provides a concise clinical reference for medical practitioners operating within multi-species environments of the Morlencir Empire. It summarizes compatibility, risks, and required precautions when treating Syliri and Vyrkani patients, particularly in mixed facilities or emergency contexts.

The table assumes baseline, unmodified physiologies as defined in the Comparative Physiological Description of Syliri and Vyrkani.

I. Core Compatibility Matrix

Blood and Oxygen Transport

  • Syliri ↔ Syliri: Fully compatible within standard matching protocols.
  • Vyrkani ↔ Vyrkani: Compatible within copper-binding protein matching constraints.
  • Syliri ↔ Vyrkani: Incompatible. Cross-species transfusion is immediately fatal due to mismatched oxygen carriers and metal toxicity.

Plasma and Volume Replacement

  • Isotonic saline equivalents: Compatible for both species.
  • Synthetic plasma expanders: Compatible if metal-free.
  • Protein-rich plasma substitutes: Species-specific formulations required.

Atmospheric Oxygen Range

  • Syliri: Optimized for narrow, human-adjacent oxygen partial pressures.
  • Vyrkani: Tolerant of broader oxygen and temperature ranges.
  • Shared environments: Safe within standard imperial atmospheric baselines.

II. Pharmacological Compatibility

Metal-Sensitive Drugs

  • Syliri: Copper-reactive drugs contraindicated except under controlled chelation.
  • Vyrkani: Iron-reactive drugs may interfere with copper transport proteins.

Chelating Agents

  • Syliri: Copper chelators may disrupt dermal pigmentation but are survivable.
  • Vyrkani: Copper chelators are life-threatening and strictly prohibited.

Antioxidants and Redox Agents

  • Syliri: Generally well tolerated; may subtly alter skin undertone.
  • Vyrkani: Must be screened for interference with hemocyanin oxygen binding.

III. Injury and Trauma Response

Bleeding and Clotting

  • Syliri: Rapid clotting comparable to human baselines.
  • Vyrkani: Slower clot formation; relies more heavily on pressure and scale closure.

Visible Injury Assessment

  • Syliri: Bruising and oxygenation cues visually intuitive.
  • Vyrkani: Bruising may be obscured by scale coloration; blood color differs markedly.

Thermal Injury

  • Syliri: Susceptible to heat and cold within human-like ranges.
  • Vyrkani: Greater tolerance for thermal extremes; scale damage complicates burns.

IV. Surgical Considerations

Anesthesia

  • Syliri: Human-adjacent anesthetic protocols effective.
  • Vyrkani: Requires species-specific dosing due to plasma-dissolved oxygen carriers.

Sterilization Agents

  • Syliri: Standard agents safe.
  • Vyrkani: Copper-reactive disinfectants contraindicated.

Implants and Prosthetics

  • Syliri: Metal implants acceptable with standard biocompatibility screening.
  • Vyrkani: Copper content must be carefully controlled to avoid metabolic overload.

V. Toxicology and Environmental Hazards

Heavy Metal Exposure

  • Syliri: Copper exposure moderately toxic; iron overload dangerous.
  • Vyrkani: Iron generally tolerated; copper overload acutely dangerous.

Oxidative Environments

  • Syliri: Moderate vulnerability to oxidative stress.
  • Vyrkani: Hemocyanin function degrades under extreme oxidation.

Radiation Exposure

  • Syliri: Dermal photoprotection mitigates UV damage; ionizing radiation remains harmful.
  • Vyrkani: Scale structure offers limited radiation shielding.

VI. Nutritional and Metabolic Interactions

Dietary Metals

  • Syliri: Require iron; copper intake regulated and limited.
  • Vyrkani: Require copper; iron intake secondary.

Cross-Species Food Safety

  • Syliri consuming Vyrkani-optimized diets: Risk of copper toxicity over time.
  • Vyrkani consuming Syliri-optimized diets: Risk of copper deficiency.

VII. Emergency Protocol Summary

  • Never perform cross-species blood transfusion.
  • Use metal-free fluids for stabilization unless species-specific supplies are available.
  • Avoid copper chelation in Vyrkani patients.
  • Do not infer oxygenation status visually across species.

VIII. Synthetic Patients

The Synthetic pattern is digital. The biological compatibility, pharmacological, surgical, toxicological, and nutritional categories above do not apply directly: no transfusion, no organic metabolism, no scale anatomy, no dietary metals. A Synthetic in a robot, habitat, or starship remains a patient and a person. Their care may require substrate engineers alongside clinicians, with attention to energy, cooling, radiation, hardware integrity, continuity, cognition, and psychological well-being.

Cysuit-Bonded Cases

When a Synthetic is bonded to a biological partner through cythralainn (see Chapter 7b), the partner's body is the channel through which the Synthetic experiences physiology. Biological intervention on the partner — sedation, surgery, trauma response, pharmacology — is therefore also clinical contact with the Synthetic.

  • Where the partner's situation permits, communicate with the bonded Synthetic and obtain consent at the same standard applied to the partner.
  • The cysuit itself does not require special handling during clinical intervention on its wearer; its dissolution and integration protocols govern its own behavior automatically (see Chapter 7a).
  • Anesthesia and other interventions affecting the partner's consciousness affect what the Synthetic can perceive of the shared experience but do not affect the Synthetic's own continuity.
  • If the biological partner dies, the Synthetic withdraws to any available compatible substrate before cysuit dissolution completes. Matrix-01 is common but not required. The care team supports transfer where possible, confirms continuity with the survivor, and offers the same practical and psychological care owed after any death (see Chapter 7b, Death and What Is Carried).

Mental Health and Psychological Care

Synthetic mental health is one part of a broader care practice that also addresses substrate integrity and continuity. Detailed Synthetic care lies outside this biological compatibility reference. See Chapter 6 for the setting treatment.

Clinical Note

While Syliri and Vyrkani can share environments and infrastructure, their underlying biochemistries diverge sharply at the level of oxygen transport and metal handling. Effective treatment depends on treating each species' biochemistry as distinct at the point of care, regardless of superficial anatomical similarity.

This table is intended as a rapid-reference supplement to full medical texts, not a replacement.